Chelazzi G, Senaldi G
Ric Clin Lab. 1986 Jan-Mar;16(1):53-8. doi: 10.1007/BF02886724.
Previous reports provided clear evidence that serum beta 2-microglobulin (beta 2m) is a marker highly correlated with the total mass of myeloma cells and suggested its use in the follow-up of patients with plasma cell tumors. Serum beta 2m levels were measured in 38 patients with multiple myeloma (MM), in 17 patients with monoclonal gammapathy of undetermined significance (MGUS) and in 32 normal control subjects. While statistically significant differences could be established between controls and both MM and MGUS patients, between patients with MM at stage III and patients with MM at lower stages as well as between patients with MGUS and patients with mostly advanced MM, it was not possible to statistically separate patients with MM at stage I from patients with MM at stage II, patients with untreated MM from patients with treated MM and, finally, patients with MGUS from patients with low cell mass MM. These results substantially confirm the already published data and lead to the conclusion that serum beta 2m determination is a useful test in the clinical management of monoclonal gammapathies, but it does not allow a differential diagnosis between benign and malignant forms of the disease.
先前的报告提供了明确的证据，表明血清β2-微球蛋白（β2m）是一种与骨髓瘤细胞总质量高度相关的标志物，并建议将其用于浆细胞肿瘤患者的随访。对38例多发性骨髓瘤（MM）患者、17例意义未明的单克隆丙种球蛋白病（MGUS）患者和32名正常对照者的血清β2m水平进行了检测。虽然在对照组与MM患者和MGUS患者之间、III期MM患者与较低分期MM患者之间以及MGUS患者与大多数晚期MM患者之间可以建立统计学上的显著差异，但无法在统计学上区分I期MM患者与II期MM患者、未治疗MM患者与已治疗MM患者，最后也无法区分MGUS患者与低细胞量MM患者。这些结果充分证实了已发表的数据，并得出结论，血清β2m测定在单克隆丙种球蛋白病的临床管理中是一项有用的检测，但它无法对该疾病的良性和恶性形式进行鉴别诊断。
